The GLP 1 fight just added a courtroom. Novo Nordisk sued Lilly in federal court, accusing its rival of misleading advertising around their obesity and diabetes drugs. Think about what this signals. Novo and Lilly already compete on efficacy, where Lilly’s tirzepatide and retatrutide have set the pace. They compete on format, where both are racing oral versions to market. They compete on access, where the Medicare Bridge opened the field to 60 million beneficiaries at $50 per month. Now they are competing in litigation.
Companies sue each other when the commercial stakes are high enough that a marketing claim is worth a federal case, and few stakes in medicine are higher than the obesity market, which analysts see topping $150 billion. When the two dominant players go to court over advertising, it tells you the competition has moved past friendly rivalry into something harder edged. For Lilly, riding high on eleven acquisitions and the strongest franchise in the industry, it is a distraction and a reputational risk. For Novo, working to close the gap after a stretch where Lilly pulled ahead on efficacy and deal count, it is a way to challenge a competitor on a front other than the clinic.
Meanwhile, Novartis opened the week’s big pharma earnings with 3% sales growth and reaffirmed 2026 guidance—a steady print after J&J’s soft open. Anthropic pushed deeper into rare disease drug development. A U.S. biotech is trying the Hong Kong IPO path. And the FDA’s comment window on its Expedited IND pilot closes today.
Novo Takes Lilly to Federal Court Over GLP 1 Advertising
What Happened: Novo Nordisk sued Lilly in federal court over what it describes as a misleading GLP 1 advertising campaign, according to The Pharma Letter and STAT.
What the Lawsuit Tells You About the State of the Obesity War
This is not just a legal dispute. It is a strategic signal about where the GLP 1 competition stands and how intense it has become.
The obesity and diabetes market is the most valuable in medicine. Lilly has Foundayo approved for obesity. Zepbound growing rapidly. Retatrutide with two pivotal wins and a projected 2027 launch at efficacy levels that match bariatric surgery. Eleven acquired companies. The Medicare Bridge covering its products at $50 per month. Retatrutide’s 28.3% weight loss is the highest ever demonstrated in a Phase 3 trial. By nearly every measure, Lilly has been winning.
Novo created the category with semaglutide, built the Wegovy franchise, secured the first MASH approval in the UK, and got oral Wegovy cleared in Europe this month. But the gap on efficacy has been real—Wegovy at 15 to 17% weight loss versus Zepbound at 22% and retatrutide at 28.3%—and Lilly’s relentless dealmaking pace has dominated the industry narrative.
When a lawsuit over advertising enters this dynamic, it tells you two things. First, the marketing claims each company is making about its drugs have become aggressive enough that the other side considers them worth litigating. In a market this large and this competitive, the way a drug is positioned in physician and patient facing materials matters enormously. A misleading claim that shifts even a small percentage of prescriptions translates into hundreds of millions of dollars. Second, the competition has expanded beyond the traditional battlegrounds of clinical data, payer coverage, and physician education into the legal system. That escalation typically happens when the stakes are so high that every available lever gets pulled.
For Lilly, the primary risk is not the legal outcome—advertising disputes in pharma are common and usually resolve through negotiated changes to marketing materials. The risk is the distraction and the reputational noise at a moment when the company is executing at the highest level in the industry. Management attention spent on litigation is attention not spent on integrating eleven acquisitions, launching retatrutide, and managing the most complex pipeline buildout in pharmaceutical history.
For Novo, the lawsuit is a way to compete on a front where Lilly’s advantages—efficacy, deal count, pipeline breadth—are less relevant. If the court finds that Lilly’s advertising crossed a line, Novo gains a tactical win that forces its competitor to modify the marketing materials that have been driving commercial adoption. Even if the case settles, the filing itself generates headlines that put Lilly’s marketing practices under public scrutiny.
The broader takeaway for the industry: the GLP 1 competition has matured into a rivalry where the players fight on data, price, format, access, and now law. That intensity is good for patients, who benefit from two companies pushing each other harder. It raises the cost of competing for everyone else in the obesity space—Pfizer, which just reshuffled its obesity discovery leadership, or Kailera, advancing its Chinese licensed oral drug—because the two incumbents are leaving no ground uncontested.
Novartis Gave Earnings Season a Steady Start
What Happened: Novartis reported 3% sales growth in Q2 and reaffirmed its 2026 guidance, a steady, in line print.
What Two Earnings Prints Tell You So Far
Two companies have reported, and together they sketch the early picture of Q2 earnings season:
J&J opened soft. Oncology sales missed expectations. Shares slipped. It was a reminder that even in a healthy market, individual franchises face competitive pressure that no amount of favorable industry conditions can override.
Novartis opened steady. Three percent growth. Guidance reaffirmed. No dramatic beats, no misses. The kind of print that tells you the underlying business is performing without setting the world on fire.
The picture forming is one we flagged Monday: a sector that is healthy but not uniformly so. The strong franchises are delivering. The weak spots are showing through. The aggregate mood coming out of BIO, the record M&A, and the reopened IPO window all suggest a buoyant industry. The earnings prints so far suggest that buoyancy is real but not evenly distributed.
Novartis has been one of the more disciplined operators among the majors this year. Its molecular glue commitment (more than $7.1 billion across four deals), the Myricx ADC payload acquisition ($1.5 billion), and the Fabhalta full approval in IgA nephropathy all demonstrate focused, strategic execution. A 3% growth print on top of that activity is not the number that makes headlines, but it is the number that tells you the machine is working.
The bigger tests come as the rest of the majors report. Lilly, with its GLP 1 franchise and fifteen deal integration challenge. AbbVie, with the Apogee close pending and Skyrizi/Rinvoq carrying the post Humira transition. Merck, with Keytruda’s clock ticking and sac TMT as the replacement horse. Pfizer, with Padcev growing but the Seagen pipeline narrowing. Each print adds detail to the picture. The question by the end of the season is whether the sector’s health is broad based or concentrated in a handful of winners.
Anthropic Pushes Deeper Into Rare Disease Drug Development
What Happened: Anthropic expanded its work applying AI to rare disease drug development, according to STAT.
Why Rare Disease Is an Interesting Proving Ground for AI
Rare diseases present a particular challenge for traditional drug development. Many of them have well defined genetic drivers—a single mutation that causes the disease is identified, the biological mechanism is understood, and the therapeutic target is clear. The problem is economics. The patient populations are tiny, often measured in the thousands or even hundreds, which means the revenue potential of a successful drug may not justify the cost of traditional development.
AI could change that equation. If computational tools can lower the cost and time of finding and designing drug candidates, conditions that were previously too expensive to develop for become viable. Target identification, molecular design, and preclinical optimization—the parts of the process where AI has already shown genuine value—are the same steps that constitute the majority of early development cost. Compressing those steps makes the economics of rare disease development less daunting.
Anthropic’s expansion into rare disease follows a broader pattern we have tracked all year. Isomorphic Labs ($2.7 billion in total funding) working with Lilly and Novartis on protein design. Insilico Medicine partnering with Takeda, SK Biopharmaceuticals ($2.5 billion), and Servier ($888 million). Lilly acquiring Profluent ($2.25 billion) for AI designed recombinases. Chai Discovery raising $400 million at a $3.8 billion valuation for molecular design. The AI drug discovery capital stack continues to grow, and each new entry targets a different part of the biological problem.
Separately, a major pharmaceutical company is building what was described as the most powerful single owned NVIDIA computing infrastructure in life sciences—a reminder that the industry is not just licensing AI tools but investing in the computational hardware to run them at scale. When a pharma company builds its own supercomputing capability rather than renting it from a cloud provider, it signals a belief that AI driven drug discovery is becoming a core competency rather than an outsourced experiment.
A U.S. Biotech Is Trying the Hong Kong IPO Path
What Happened: Axiom Biosciences plans to go public in Hong Kong rather than the United States, according to BioSpace.
Why This Matters: Hong Kong has become a major venue for biotech listings, particularly for companies with Asian strategies or Chinese investor appeal. Its listing rules have evolved to welcome pre revenue biotechs, and its investor base has developed genuine appetite for the sector. A U.S. company choosing Hong Kong signals both the depth of Asian capital and the appeal of positioning as a global company rather than a purely domestic one.
The move also reflects the broader dynamic we have tracked all year. As Chinese science and capital have become central to the pharmaceutical industry—more than 100 licensing pacts between Chinese and U.S. companies, $138 billion in Chinese asset licensing in 2025—the lines between U.S. and Asian biotech are blurring. A U.S. company listing in Hong Kong is the capital markets expression of the same trend that has Western pharma licensing Chinese assets and building companies around them.
It comes as 2026 tracks toward the most biotech IPOs since the 2021 peak, with 18 companies public so far. Whether Axiom’s path becomes a template or a curiosity depends on its reception. If it prices well and trades well, expect other U.S. biotechs with Asian strategies to consider the route. If it struggles, it stays an interesting experiment. Either way, the willingness to try tells you how global the competition for biotech capital has become. The U.S. public market is no longer the only venue, and in a year where the IPO window is the healthiest in five years, the venues themselves are now in competition.
Quick Hits
Agios discontinued tebapivat for sickle cell disease after a Phase 2 study failed to establish a differentiated profile. A clean example of the fast prioritization calls that cash conscious biotechs keep making throughout 2026—cut what is not working, preserve capital for what might.
Dyne Therapeutics got an early 2027 decision date for its Duchenne muscular dystrophy therapy, with analysts expecting a smooth review. It adds to the busy Duchenne regulatory calendar that already includes Capricor’s deramiocel (August 22 PDUFA, advisory committee pending) and REGENXBIO’s gene therapy BLA filing expected in Q3.
EMD Serono may trim its R&D workforce by up to 70, per BioSpace’s layoff tracker. EMD Serono is the U.S. healthcare arm of Merck KGaA, and the cuts come as the company integrates its $11.3 billion Bio Techne acquisition—a reminder that even deals celebrated for their strategic logic come with human cost during integration.
Lonza and Engitix teamed up on targeted ADC development, more evidence of the CDMO sector building specialized capability in the industry’s hottest modality. The ADC manufacturing demand from Enhertu, sac TMT, Padcev, and dozens of clinical stage programs is pushing CDMOs to invest in conjugation chemistry expertise that most did not have five years ago.
The FDA’s comment window on the Expedited IND pilot closes today (July 22). The pilot, part of Operation TrialBlazer’s effort to bring clinical trials back to the U.S. from China, would streamline the IND process to cut six to twelve months off early development timelines. We covered TrialBlazer’s limitations last week—it addresses the regulatory bottleneck but not the operational ones (site activation, IRB patchwork, patient recruitment) that actually determine speed to first patient.
Strategic Themes
1. The GLP 1 Competition Has Escalated to Federal Court, and That Tells You Everything About the Stakes
Novo suing Lilly over advertising is not about one marketing claim. It is about the scale of what is being contested. A $150 billion plus market. Two companies with fundamentally different competitive positions—Lilly pulling ahead on efficacy and deal count, Novo defending the franchise it created. When the rivalry reaches the courtroom, every available competitive lever is being used. The lawsuit is a symptom of how consequential the GLP 1 market has become.
2. Two Earnings Prints Say the Sector Is Healthy but Not Uniformly So
J&J soft. Novartis steady. The early picture is consistent with what we expected: a sector that is broadly healthy, where the strong franchises deliver and the weak spots show through. The test comes as the bigger names—Lilly, AbbVie, Merck, Pfizer—report over the next week. If the pattern holds (strong where franchises are performing, weak where competition is biting), the second half outlook remains constructive. If the misses cluster, the narrative gets more complicated.
3. AI in Rare Disease Could Change What Is Commercially Viable
Rare diseases have clear biology but tiny markets. AI could lower development costs enough to make conditions viable that were previously too expensive to pursue. Anthropic’s expansion into rare disease, alongside the broader AI drug discovery capital stack exceeding $9 billion in commitments, suggests the industry sees AI not just as a tool for accelerating big market drugs but as a way to unlock categories that the traditional development model cannot serve profitably.
4. The Hong Kong IPO Experiment Reflects How Global Biotech Capital Has Become
A U.S. company choosing Hong Kong over Nasdaq is a data point about the global competition for biotech investment dollars. In a year tracking toward the most IPOs since 2021, the venues themselves are competing for listings. If Axiom succeeds, the path opens for other U.S. biotechs with Asian strategies. If it does not, the U.S. market remains the default. Either way, the attempt tells you something about how far the industry’s center of gravity has shifted from a purely domestic phenomenon to a global one.
Frequently Asked Questions
Why did Novo sue Lilly?
Novo Nordisk filed a federal lawsuit accusing Lilly of misleading GLP 1 advertising. The two dominant obesity and diabetes companies already compete on efficacy, format, and access. The lawsuit adds a legal front to a rivalry where the stakes exceed $150 billion. It signals the competition has intensified beyond clinical and commercial battlegrounds into the courtroom.
How did Novartis earnings look?
Three percent sales growth in Q2, guidance reaffirmed. A steady, in line print that contrasts with J&J’s soft oncology driven miss. Together the two prints suggest a sector that is healthy but not uniformly so—strong franchises delivering, weak spots showing.
What is Anthropic doing in rare disease?
Expanding its AI work into rare disease drug development. Rare diseases often have clear genetic drivers but tiny patient populations that make traditional development economics challenging. AI could lower costs enough to make previously unviable conditions worth pursuing.
What is the Axiom Hong Kong IPO?
A U.S. biotech planning to go public in Hong Kong rather than the United States. It reflects the global competition for biotech capital and the blurring of lines between U.S. and Asian biotech. 2026 tracks toward the most IPOs since 2021 with 18 companies public.
What happened with Agios?
Discontinued tebapivat for sickle cell disease after Phase 2 failed to show a differentiated profile. Another example of fast prioritization by cash conscious biotechs in 2026.
When do the other big pharmas report?
Over the next week. Lilly, AbbVie, Merck, and Pfizer among others. The prints will test whether the sector’s optimism is broadly supported or concentrated in specific winners.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Novo Suing Lilly Is About More Than Ads. We analyze what the litigation reveals about the state of the obesity war, who benefits from the courtroom fight, and whether it stays narrow or escalates into a broader legal campaign that consumes real management attention on both sides.
Earnings Are Painting an Uneven Picture. We assess what Novartis steady and J&J soft tells you about the second half, identify the franchises most likely to surprise or disappoint as the bigger names report, and evaluate whether the aggregate confirms or complicates the buoyant sector narrative.
A US Biotech Chose Hong Kong. We lay out whether the Asian IPO path is a real alternative for U.S. companies, what it means for the global competition for biotech capital, and which types of companies are most likely to follow if Axiom succeeds.
Plus: Anthropic rare disease AI, Agios sickle cell discontinuation, EMD Serono integration cuts, Lonza ADC capability build, FDA Expedited IND comment window closing, Section 232 countdown (9 days), and the full H2 catalyst calendar.
Upgrade to BioMed Nexus Pro →
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
Subscribe to BioMed Nexus →
Novo Sued Lilly, and the GLP 1 War Went to Court
Table of Contents
The GLP 1 fight just added a courtroom. Novo Nordisk sued Lilly in federal court, accusing its rival of misleading advertising around their obesity and diabetes drugs. Think about what this signals. Novo and Lilly already compete on efficacy, where Lilly’s tirzepatide and retatrutide have set the pace. They compete on format, where both are racing oral versions to market. They compete on access, where the Medicare Bridge opened the field to 60 million beneficiaries at $50 per month. Now they are competing in litigation.
Companies sue each other when the commercial stakes are high enough that a marketing claim is worth a federal case, and few stakes in medicine are higher than the obesity market, which analysts see topping $150 billion. When the two dominant players go to court over advertising, it tells you the competition has moved past friendly rivalry into something harder edged. For Lilly, riding high on eleven acquisitions and the strongest franchise in the industry, it is a distraction and a reputational risk. For Novo, working to close the gap after a stretch where Lilly pulled ahead on efficacy and deal count, it is a way to challenge a competitor on a front other than the clinic.
Meanwhile, Novartis opened the week’s big pharma earnings with 3% sales growth and reaffirmed 2026 guidance—a steady print after J&J’s soft open. Anthropic pushed deeper into rare disease drug development. A U.S. biotech is trying the Hong Kong IPO path. And the FDA’s comment window on its Expedited IND pilot closes today.
Novo Takes Lilly to Federal Court Over GLP 1 Advertising
What Happened: Novo Nordisk sued Lilly in federal court over what it describes as a misleading GLP 1 advertising campaign, according to The Pharma Letter and STAT.
What the Lawsuit Tells You About the State of the Obesity War
This is not just a legal dispute. It is a strategic signal about where the GLP 1 competition stands and how intense it has become.
The obesity and diabetes market is the most valuable in medicine. Lilly has Foundayo approved for obesity. Zepbound growing rapidly. Retatrutide with two pivotal wins and a projected 2027 launch at efficacy levels that match bariatric surgery. Eleven acquired companies. The Medicare Bridge covering its products at $50 per month. Retatrutide’s 28.3% weight loss is the highest ever demonstrated in a Phase 3 trial. By nearly every measure, Lilly has been winning.
Novo created the category with semaglutide, built the Wegovy franchise, secured the first MASH approval in the UK, and got oral Wegovy cleared in Europe this month. But the gap on efficacy has been real—Wegovy at 15 to 17% weight loss versus Zepbound at 22% and retatrutide at 28.3%—and Lilly’s relentless dealmaking pace has dominated the industry narrative.
When a lawsuit over advertising enters this dynamic, it tells you two things. First, the marketing claims each company is making about its drugs have become aggressive enough that the other side considers them worth litigating. In a market this large and this competitive, the way a drug is positioned in physician and patient facing materials matters enormously. A misleading claim that shifts even a small percentage of prescriptions translates into hundreds of millions of dollars. Second, the competition has expanded beyond the traditional battlegrounds of clinical data, payer coverage, and physician education into the legal system. That escalation typically happens when the stakes are so high that every available lever gets pulled.
For Lilly, the primary risk is not the legal outcome—advertising disputes in pharma are common and usually resolve through negotiated changes to marketing materials. The risk is the distraction and the reputational noise at a moment when the company is executing at the highest level in the industry. Management attention spent on litigation is attention not spent on integrating eleven acquisitions, launching retatrutide, and managing the most complex pipeline buildout in pharmaceutical history.
For Novo, the lawsuit is a way to compete on a front where Lilly’s advantages—efficacy, deal count, pipeline breadth—are less relevant. If the court finds that Lilly’s advertising crossed a line, Novo gains a tactical win that forces its competitor to modify the marketing materials that have been driving commercial adoption. Even if the case settles, the filing itself generates headlines that put Lilly’s marketing practices under public scrutiny.
The broader takeaway for the industry: the GLP 1 competition has matured into a rivalry where the players fight on data, price, format, access, and now law. That intensity is good for patients, who benefit from two companies pushing each other harder. It raises the cost of competing for everyone else in the obesity space—Pfizer, which just reshuffled its obesity discovery leadership, or Kailera, advancing its Chinese licensed oral drug—because the two incumbents are leaving no ground uncontested.
Novartis Gave Earnings Season a Steady Start
What Happened: Novartis reported 3% sales growth in Q2 and reaffirmed its 2026 guidance, a steady, in line print.
What Two Earnings Prints Tell You So Far
Two companies have reported, and together they sketch the early picture of Q2 earnings season:
J&J opened soft. Oncology sales missed expectations. Shares slipped. It was a reminder that even in a healthy market, individual franchises face competitive pressure that no amount of favorable industry conditions can override.
Novartis opened steady. Three percent growth. Guidance reaffirmed. No dramatic beats, no misses. The kind of print that tells you the underlying business is performing without setting the world on fire.
The picture forming is one we flagged Monday: a sector that is healthy but not uniformly so. The strong franchises are delivering. The weak spots are showing through. The aggregate mood coming out of BIO, the record M&A, and the reopened IPO window all suggest a buoyant industry. The earnings prints so far suggest that buoyancy is real but not evenly distributed.
Novartis has been one of the more disciplined operators among the majors this year. Its molecular glue commitment (more than $7.1 billion across four deals), the Myricx ADC payload acquisition ($1.5 billion), and the Fabhalta full approval in IgA nephropathy all demonstrate focused, strategic execution. A 3% growth print on top of that activity is not the number that makes headlines, but it is the number that tells you the machine is working.
The bigger tests come as the rest of the majors report. Lilly, with its GLP 1 franchise and fifteen deal integration challenge. AbbVie, with the Apogee close pending and Skyrizi/Rinvoq carrying the post Humira transition. Merck, with Keytruda’s clock ticking and sac TMT as the replacement horse. Pfizer, with Padcev growing but the Seagen pipeline narrowing. Each print adds detail to the picture. The question by the end of the season is whether the sector’s health is broad based or concentrated in a handful of winners.
Anthropic Pushes Deeper Into Rare Disease Drug Development
What Happened: Anthropic expanded its work applying AI to rare disease drug development, according to STAT.
Why Rare Disease Is an Interesting Proving Ground for AI
Rare diseases present a particular challenge for traditional drug development. Many of them have well defined genetic drivers—a single mutation that causes the disease is identified, the biological mechanism is understood, and the therapeutic target is clear. The problem is economics. The patient populations are tiny, often measured in the thousands or even hundreds, which means the revenue potential of a successful drug may not justify the cost of traditional development.
AI could change that equation. If computational tools can lower the cost and time of finding and designing drug candidates, conditions that were previously too expensive to develop for become viable. Target identification, molecular design, and preclinical optimization—the parts of the process where AI has already shown genuine value—are the same steps that constitute the majority of early development cost. Compressing those steps makes the economics of rare disease development less daunting.
Anthropic’s expansion into rare disease follows a broader pattern we have tracked all year. Isomorphic Labs ($2.7 billion in total funding) working with Lilly and Novartis on protein design. Insilico Medicine partnering with Takeda, SK Biopharmaceuticals ($2.5 billion), and Servier ($888 million). Lilly acquiring Profluent ($2.25 billion) for AI designed recombinases. Chai Discovery raising $400 million at a $3.8 billion valuation for molecular design. The AI drug discovery capital stack continues to grow, and each new entry targets a different part of the biological problem.
Separately, a major pharmaceutical company is building what was described as the most powerful single owned NVIDIA computing infrastructure in life sciences—a reminder that the industry is not just licensing AI tools but investing in the computational hardware to run them at scale. When a pharma company builds its own supercomputing capability rather than renting it from a cloud provider, it signals a belief that AI driven drug discovery is becoming a core competency rather than an outsourced experiment.
A U.S. Biotech Is Trying the Hong Kong IPO Path
What Happened: Axiom Biosciences plans to go public in Hong Kong rather than the United States, according to BioSpace.
Why This Matters: Hong Kong has become a major venue for biotech listings, particularly for companies with Asian strategies or Chinese investor appeal. Its listing rules have evolved to welcome pre revenue biotechs, and its investor base has developed genuine appetite for the sector. A U.S. company choosing Hong Kong signals both the depth of Asian capital and the appeal of positioning as a global company rather than a purely domestic one.
The move also reflects the broader dynamic we have tracked all year. As Chinese science and capital have become central to the pharmaceutical industry—more than 100 licensing pacts between Chinese and U.S. companies, $138 billion in Chinese asset licensing in 2025—the lines between U.S. and Asian biotech are blurring. A U.S. company listing in Hong Kong is the capital markets expression of the same trend that has Western pharma licensing Chinese assets and building companies around them.
It comes as 2026 tracks toward the most biotech IPOs since the 2021 peak, with 18 companies public so far. Whether Axiom’s path becomes a template or a curiosity depends on its reception. If it prices well and trades well, expect other U.S. biotechs with Asian strategies to consider the route. If it struggles, it stays an interesting experiment. Either way, the willingness to try tells you how global the competition for biotech capital has become. The U.S. public market is no longer the only venue, and in a year where the IPO window is the healthiest in five years, the venues themselves are now in competition.
Quick Hits
Agios discontinued tebapivat for sickle cell disease after a Phase 2 study failed to establish a differentiated profile. A clean example of the fast prioritization calls that cash conscious biotechs keep making throughout 2026—cut what is not working, preserve capital for what might.
Dyne Therapeutics got an early 2027 decision date for its Duchenne muscular dystrophy therapy, with analysts expecting a smooth review. It adds to the busy Duchenne regulatory calendar that already includes Capricor’s deramiocel (August 22 PDUFA, advisory committee pending) and REGENXBIO’s gene therapy BLA filing expected in Q3.
EMD Serono may trim its R&D workforce by up to 70, per BioSpace’s layoff tracker. EMD Serono is the U.S. healthcare arm of Merck KGaA, and the cuts come as the company integrates its $11.3 billion Bio Techne acquisition—a reminder that even deals celebrated for their strategic logic come with human cost during integration.
Lonza and Engitix teamed up on targeted ADC development, more evidence of the CDMO sector building specialized capability in the industry’s hottest modality. The ADC manufacturing demand from Enhertu, sac TMT, Padcev, and dozens of clinical stage programs is pushing CDMOs to invest in conjugation chemistry expertise that most did not have five years ago.
The FDA’s comment window on the Expedited IND pilot closes today (July 22). The pilot, part of Operation TrialBlazer’s effort to bring clinical trials back to the U.S. from China, would streamline the IND process to cut six to twelve months off early development timelines. We covered TrialBlazer’s limitations last week—it addresses the regulatory bottleneck but not the operational ones (site activation, IRB patchwork, patient recruitment) that actually determine speed to first patient.
Strategic Themes
1. The GLP 1 Competition Has Escalated to Federal Court, and That Tells You Everything About the Stakes
Novo suing Lilly over advertising is not about one marketing claim. It is about the scale of what is being contested. A $150 billion plus market. Two companies with fundamentally different competitive positions—Lilly pulling ahead on efficacy and deal count, Novo defending the franchise it created. When the rivalry reaches the courtroom, every available competitive lever is being used. The lawsuit is a symptom of how consequential the GLP 1 market has become.
2. Two Earnings Prints Say the Sector Is Healthy but Not Uniformly So
J&J soft. Novartis steady. The early picture is consistent with what we expected: a sector that is broadly healthy, where the strong franchises deliver and the weak spots show through. The test comes as the bigger names—Lilly, AbbVie, Merck, Pfizer—report over the next week. If the pattern holds (strong where franchises are performing, weak where competition is biting), the second half outlook remains constructive. If the misses cluster, the narrative gets more complicated.
3. AI in Rare Disease Could Change What Is Commercially Viable
Rare diseases have clear biology but tiny markets. AI could lower development costs enough to make conditions viable that were previously too expensive to pursue. Anthropic’s expansion into rare disease, alongside the broader AI drug discovery capital stack exceeding $9 billion in commitments, suggests the industry sees AI not just as a tool for accelerating big market drugs but as a way to unlock categories that the traditional development model cannot serve profitably.
4. The Hong Kong IPO Experiment Reflects How Global Biotech Capital Has Become
A U.S. company choosing Hong Kong over Nasdaq is a data point about the global competition for biotech investment dollars. In a year tracking toward the most IPOs since 2021, the venues themselves are competing for listings. If Axiom succeeds, the path opens for other U.S. biotechs with Asian strategies. If it does not, the U.S. market remains the default. Either way, the attempt tells you something about how far the industry’s center of gravity has shifted from a purely domestic phenomenon to a global one.
Frequently Asked Questions
Why did Novo sue Lilly?
Novo Nordisk filed a federal lawsuit accusing Lilly of misleading GLP 1 advertising. The two dominant obesity and diabetes companies already compete on efficacy, format, and access. The lawsuit adds a legal front to a rivalry where the stakes exceed $150 billion. It signals the competition has intensified beyond clinical and commercial battlegrounds into the courtroom.
How did Novartis earnings look?
Three percent sales growth in Q2, guidance reaffirmed. A steady, in line print that contrasts with J&J’s soft oncology driven miss. Together the two prints suggest a sector that is healthy but not uniformly so—strong franchises delivering, weak spots showing.
What is Anthropic doing in rare disease?
Expanding its AI work into rare disease drug development. Rare diseases often have clear genetic drivers but tiny patient populations that make traditional development economics challenging. AI could lower costs enough to make previously unviable conditions worth pursuing.
What is the Axiom Hong Kong IPO?
A U.S. biotech planning to go public in Hong Kong rather than the United States. It reflects the global competition for biotech capital and the blurring of lines between U.S. and Asian biotech. 2026 tracks toward the most IPOs since 2021 with 18 companies public.
What happened with Agios?
Discontinued tebapivat for sickle cell disease after Phase 2 failed to show a differentiated profile. Another example of fast prioritization by cash conscious biotechs in 2026.
When do the other big pharmas report?
Over the next week. Lilly, AbbVie, Merck, and Pfizer among others. The prints will test whether the sector’s optimism is broadly supported or concentrated in specific winners.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
Novo Suing Lilly Is About More Than Ads. We analyze what the litigation reveals about the state of the obesity war, who benefits from the courtroom fight, and whether it stays narrow or escalates into a broader legal campaign that consumes real management attention on both sides.
Earnings Are Painting an Uneven Picture. We assess what Novartis steady and J&J soft tells you about the second half, identify the franchises most likely to surprise or disappoint as the bigger names report, and evaluate whether the aggregate confirms or complicates the buoyant sector narrative.
A US Biotech Chose Hong Kong. We lay out whether the Asian IPO path is a real alternative for U.S. companies, what it means for the global competition for biotech capital, and which types of companies are most likely to follow if Axiom succeeds.
Plus: Anthropic rare disease AI, Agios sickle cell discontinuation, EMD Serono integration cuts, Lonza ADC capability build, FDA Expedited IND comment window closing, Section 232 countdown (9 days), and the full H2 catalyst calendar.
Upgrade to BioMed Nexus Pro →
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
Subscribe to BioMed Nexus →
Featured Articles
Biotech Sales Email Templates That Actually Get Replies
Why most cold emails to biopharma fail, and the trigger based outreach approach that works. Ten sequences tied to real events, with subject lines that get opened.
Life Sciences Conferences 2026 to 2027: Dates, Venues, and Which to Attend
A full calendar of the major biotech and pharma conferences through 2027, with verified dates and venues, plus which events are worth a booth and which are not.
How to Reach Biotech Buyers: A Channel by Channel Cost Guide
What it actually costs to reach a biotech buyer across twelve marketing channels, what each is good for, and the one calculation that makes them all comparable.